目的 比较在超声引导下甲状腺结节细针穿刺活检中不同穿刺针数的标本满意率，为临床操作提供依据。 方法 纳入我院95例患者，共计106个实性或实性为主的甲状腺结节，随机分为1针组、2针组和3针组，均在超声引导下完成对甲状腺实性成分的细针穿刺活检术，标本送细胞病理学诊断，依据Bethesda分类标准，将BethesdaⅠ类定义为不满意，BethesdaⅡ~Ⅵ类定义为满意，比较不同穿刺针数的标本满意率。 结果 结节标本总体满意率为92.5%（98/106），1针组、2针组、3针组的标本满意率分别为90.2%（37/41）、93.9%（31/33）、93.8%（30/32），三组差异无统计学意义（P＞0.05）。 结论 对于实性或以实性为主的甲状腺结节，超声引导下细针穿刺的针数对取材的影响不明显，穿刺1针可以达到和2针、3针相当的标本满意率。
Abstract
Objective To compare the sample satisfaction rate of different needle passes in ultrasound-guided fine-needle aspiration biopsy of thyroid nodules, and provide the basis for clinic operation. Methods Ninety-five patients with 106 solid or mainly solid thyroid nodules were included in our hospital and randomly divided into a one-needle passes group, a two-needle passes group, a three-needle passes group. Fine needle aspiration biopsy of thyroid was performed under ultrasonic guidance. The obtained specimens were sent for cytopathological diagnosis which was classified according to the Bethesda System. Bethesda I was defined as unsatisfactory, and Bethesda Ⅱ~Ⅵ were defined as satisfactory. The satisfaction rate of specimens with different number of passes needles was compared. Results The overall satisfaction rate of nodule samples was 92.5% (98/106). There were no statistical differences in the satisfaction rate among the one-needle passes group, two-needle passes group, and three-needle passes group (90.2%, 93.9%, and 93.8%, respectively, P>0.05). Conclusions For solid or mainly solid thyroid nodules, the number of needle passes guided by ultrasound has no significant effect on sampling and the satisfaction rate of specimen with one needle passes is equivalent to that with 2 or 3 needles.
关键词
甲状腺结节细针穿刺 /
穿刺针数 /
标本满意率
Key words
Fine-needle aspiration of thyroid nodules /
Number of needle passes /
Satisfaction rate of sampling
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] de Koster EJ, Kist JW, Vriens MR, et al. Thyroid ultrasound-guided fine-needle Aspiration: the positive influence of on-site adequacy assessment and number of needle passes on diagnostic cytology rate[J]. Acta Cytol, 2016, 60(1): 39-45. DOI: 10.1159/000444917.
[2] Reuters KB, Mamone MCOC, Ikejiri ES, et al. Bethesda classification and cytohistological correlation of thyroid nodules in a brazilian thyroid disease center[J]. Eur Thyroid J, 2018, 7(3): 133-138. DOI: 10.1159/000488104.
[3] Abraham TM, de las Morenas A, Lee SL, et al. In thyroid fine-needle aspiration, use of bedside-prepared slides significantly increased diagnostic adequacy and specimen cellularity relative to solution-based samples[J]. Thyroid, 2011, 21(3): 237-242. DOI: 10.1089/thy.2010.0211.
[4] Cibas ES, Ali SZ. The 2017 bethesda system for reporting thyroid cytopathology[J]. J Am Soc Cytopathol, 2017, 6(6): 217-222. DOI: 10.1016/j.jasc.2017.09.002.
[5] Pitman MB, Abele J, Ali SZ, et al. Techniques for thyroid FNA: a synopsis of the national cancer institute thyroid fine-needle aspiration state of the science conference[J]. Diagn Cytopathol, 2008, 36(6): 407-424. DOI: 10.1002/dc.20829.
[6] Gharib H, Papini E, Garber JR, et al. American association of clinical endocrinologists, american college of endocrinology, and associazione medici endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules-2016 update[J]. Endocr Pract, 2016, 22(5): 622-639. DOI: 10.4158/EP161208.GL.
[7] Zheng BW, Zarka MA, Chen CD, et al. The largest CAP-certified Chinese reference laboratory experience with the Bethesda system for reporting thyroid cytopathology: correlation with histologic and BRAF data[J]. J Am Soc Cytopathol, 2018, 7(1): 16-21. DOI: 10.1016/j.jasc.2017.07.002.
[8] Kuzan TY, Goret CC. Comparison of number of passes and cytopathological specimen adequacy for thyroid fine-needle aspiration biopsy in the absence of an on-site pathologist[J]. Eur Thyroid J, 2020, 9(1): 49-54. DOI: 10.1159/000504094.
[9] Zhu WJ, Michael CW. How important is on-site adequacy assessment for thyroid FNA? An evaluation of 883 cases[J]. Diagn Cytopathol, 2007, 35(3): 183-186. DOI: 10.1002/dc.20552.
[10]Pastorello RG, Destefani C, Pinto PH, et al. The impact of rapid on-site evaluation on thyroid fine-needle aspiration biopsy: a 2-year cancer center institutional experience[J]. Cancer Cytopathol, 2018, 126(10): 846-852. DOI: 10.1002/cncy.22051.
[11]Shrestha M, Crothers BA, Burch HB. The impact of thyroid nodule size on the risk of malignancy and accuracy of fine-needle aspiration: a 10-year study from a single institution[J]. Thyroid, 2012, 22(12): 1251-1256. DOI: 10.1089/thy.2012.0265.
[12]Paschke R, Hegedüs L, Alexander E, et al. Thyroid nodule guidelines: agreement, disagreement and need for future research[J]. Nat Rev Endocrinol, 2011, 7(6): 354-361. DOI: 10.1038/nrendo.2011.1.
[13]Grani G, Calvanese A, Carbotta G, et al. Intrinsic factors affecting adequacy of thyroid nodule fine-needle aspiration cytology[J]. Clin Endocrinol (Oxf), 2013, 78(1): 141-144. DOI: 10.1111/j.1365-2265.2012.04507.x.
[14]Zargham R, Johnson H, Anderson S, et al. Conditions associated with the need for additional needle passes in ultrasound-guided thyroid fine-needle aspiration with rapid on-site pathology evaluation[J]. Diagn Cytopathol, 2021, 49(1): 105-108. DOI: 10.1002/dc.24605.
[15]Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133. DOI: 10.1089/thy.2015.0020.
PDF(1309 KB)
京ICP备08002354号-3
